양성전립선비대증 증상 조절을 위해 투여되는 알파차단제의 골절위험
The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objectives : We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH). Methods : We used the Health Insurance Review and Assessment Service database from January 1st 2005 to June 30th 2006 for this study. The male patients with BPH and who had a prescription for alpha blockers following any fractures were defined as the cases. We set the 20 day long hazard period prior to the index date and the four control periods whose lengths were same with hazard period. After 1:4 matching of the hazard and control periods, conditional logistic regression was used to calculate the odds ratios for the risk of fractures as related to the alpha blocker exposure. Results : Doxazosin and tamsulosin showed the increased risk of fractures, whereas terazosin did not. After stratification using the defined daily doses, a protective effect was shown for the patients who took terazosin at the doses lower than 0.4 DDD and the hazardous effect at the doses higher than or equal to 0.4 DDD. There was no significant difference for the risk of patients taking tamsulosin at the doses higher than 1.0 DDD but there was a statistically significant increase in the risk at the doses higher than or equal to 1.0 DDD. Conclusions : Alpha blockers for BPH may increase the risk of fracture in elderly patients who have comorbidities and take the concomitant medications. Alpha blockers need to be prescribed with caution, although some have high prostate specificity.
Abstract
Objectives : We evaluated the risk of fracture associated with hypotension-related adverse drug reaction caused by taking alpha blockers to treat benign prostatic hyperplasia (BPH). Methods : We used the Health Insurance Review and Assessment Service database from January 1st 2005 to June 30th 2006 for this study. The male patients with BPH and who had a prescription for alpha blockers following any fractures were defined as the cases. We set the 20 day long hazard period prior to the index date and the four control periods whose lengths were same with hazard period. After 1:4 matching of the hazard and control periods, conditional logistic regression was used to calculate the odds ratios for the risk of fractures as related to the alpha blocker exposure. Results : Doxazosin and tamsulosin showed the increased risk of fractures, whereas terazosin did not. After stratification using the defined daily doses, a protective effect was shown for the patients who took terazosin at the doses lower than 0.4 DDD and the hazardous effect at the doses higher than or equal to 0.4 DDD. There was no significant difference for the risk of patients taking tamsulosin at the doses higher than 1.0 DDD but there was a statistically significant increase in the risk at the doses higher than or equal to 1.0 DDD. Conclusions : Alpha blockers for BPH may increase the risk of fracture in elderly patients who have comorbidities and take the concomitant medications. Alpha blockers need to be prescribed with caution, although some have high prostate specificity.
참고문헌 (17)
- Arrighi HM, "Natural history of benign prostatic hyperplasia and risk of prostatectomy", Urology, 38(1), pp.4~8 (1991)
- "Korean Census 2005"[URL]
- Lee E, "A high risk group for prostatism: A population-based epidemiological study in Korea", Br J Urol, 79(5), pp.736~741 (1997)
- Stoevelaar HJ, "Changing therapeutic regimens in benign prostatic hyperplasia", Pharmacoeconomics, 19(2), pp.131~153 (2001)
- 한경석, "최근 5년간 관찰한 전립선비대증 환자의 치료 경향의 변화", Korean Journal of Urology, 46(5), pp.458~462 (2005), 대한비뇨기과학회
- AUA Practice Guidelines Committee, "Guideline on the management of benign prostatic hyperplasia", J Urol, 170(2 Pt 1), pp.530~547 (2003)
- Djavan B, "State of the art on the efficacy and tolerability of the alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia", J Urol, 64(6), pp.1081~1088 (2004)
- Maclure M, "Why me? versus why now? - differences between operational hypothesis in case control versus case-crossover studies", Pharmacoepidemiol Drug Saf, 16(8), pp.850~853 (2007)
- Chrischilles E, "Initiation of nonselective alpha1 antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: A retrospective cohort study", Clin Ther, 23(5), pp.727~743 (2001)
- Souverein PC, "Use of alpha blockers and the risk of hip", femur fractures, 2003, pp.254(6), 548~554
- McMahon AD, "Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology", Pharmacoepidemiol Drug Saf, 7(4), pp.275~280 (1998)
- Maclure M, "The case-crossover design: A method for studying transient effects on the risk of acute events", Am J Epidemiol, 133(2), pp.144~153 (1991)
- McConnell JD, "The long-term effect of doxazosin, finasteride,and combination therapy on the clinical progression of benign prostatic hyperplasia", N Engl J Med, 349(25), pp.2387~2398 (2003)
- Hartikainen S, "Medication as a risk factor for falls: Critical systematic review", J Gerontol A Biol Sci Med Sci, 62(10), pp.1172~1181 (2007)
- Macdonald R, "Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: A systematic review of efficacy and adverse effects", BJU Int, 94(9), pp.1263~1270 (2004)
- Milani S, "Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on a1-adrenoceptor antagonists", BJU Int, 95(4), pp.29~36 (2005)
- Hall GC, "Comparative study of modified release alpha blocker exposure inelderly patients with fractures", Pharmacoepidemiol Drug Saf, 16(8), pp.901~907 (2007)